半年连融两轮！智冉医疗完成3亿元A+轮融资，中科创星领投

Core Insights - The article highlights that Zhiran Medical, a leading domestic invasive brain-computer interface (BCI) company, has completed a 300 million yuan A+ round of financing, led by Zhongke Chuangxing, with participation from various investors [1] - The funding will primarily be used to advance large-scale clinical trials and iterate high-throughput flexible BCI products, accelerating the technology's clinical application [1] - Zhiran Medical is committed to the invasive BCI technology route, believing it is essential for achieving high-bandwidth information exchange between the human brain and external devices, evolving BCIs from assistive tools to core technologies for efficient human-machine symbiosis [1] Company Developments - Zhiran Medical has established a systematic layout in the invasive BCI industry chain, achieving a complete industrial closed loop from core technology research and development to large-scale production [3] - The company has made significant breakthroughs in key technologies, including flexible electrodes, neural chips, decoding algorithms, and electrode implantation robots, ensuring full control over clinical-grade products [3][6] - A recent breakthrough includes the development of a stretchable high-throughput flexible electrode, which addresses industry challenges related to traditional linear flexible electrodes [3][6] Technological Advancements - The company's domestically produced neural signal acquisition chip is coin-sized and has reduced power consumption by 75% compared to traditional chips [6] - The deep neural network decoding algorithm, trained on vast amounts of neural data, enables high-precision real-time decoding [6] - Zhiran Medical has successfully developed a high-throughput wireless invasive BCI system based on stretchable flexible electrodes, enhancing signal stability and decoding accuracy for large-scale clinical applications [6] Clinical Applications - By 2025, Zhiran Medical completed the first clinical implantation of an invasive BCI product with over 100 channels, preliminarily verifying its safety and effectiveness [6] - The company plans to initiate large-scale registration clinical trials for its over 100-channel invasive BCI product in 2026, accelerating its clinical rollout [6] Industry Position - As a leader in the domestic invasive BCI field, Zhiran Medical aligns with the national "14th Five-Year Plan" for future industry development and responds to the country's call for independent innovation in cutting-edge technologies [7] - The company aims to continue accelerating core technology breakthroughs and clinical transformation processes, contributing to China's leadership in the invasive BCI sector [8]